Our latest U.S. FDA submission reflects our dedication to advancing innovative therapies for patients with newly diagnosed #MultipleMyeloma for whom transplant is not planned. We continue to strive toward transforming outcomes for this complex disease: t.co/C88LURYRET t.co/mpu9gxz8jy